Division of Pathology, The Cancer Institute of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Breast Cancer Res Treat. 2019 Feb;174(1):103-111. doi: 10.1007/s10549-018-5068-4. Epub 2018 Nov 24.
Ductal carcinoma in situ (DCIS)-preinvasive breast cancer-with lymph node metastasis can clinically be treated as different stages: occult invasive cancer with true metastasis (T1N1) or pure DCIS with iatrogenic dissemination (TisN0). In this retrospective cohort study, we aimed to elucidate the prognostic impact and possible pathogenesis of nodal metastasis in DCIS to improve clinical management.
Subjects were comprised of 427 patients with routine postoperative diagnosis of DCIS who underwent sentinel node (SN) biopsy using molecular whole-lymph-node analysis. Clinicopathological characteristics and prognosis were compared between SN-positive and -negative patients. Primary tumour tissues of SN-positive patients were exhaustively step-sectioned to detect occult invasions, and predictive factors for occult invasion were investigated. Median follow-up time was 73.6 months.
Of the 427 patients, 19 (4.4%) were SN-positive and 408 (95.6%) were SN-negative. More SN-positive patients received adjuvant systemic therapy than SN-negative patients (84.2% vs. 5.4%). Seven-year distant disease-free survivals were favourable for both cohorts (SN-positive, 100%; SN-negative, 99.7%). By examining 1421 slides, occult invasion was identified in 9 (47.4%) of the 19 SN-positive patients. Tumour burdens in SN and incidence of non-SN metastasis were similar between patients with and without occult invasion, and no predictive factor for occult invasion was found.
Node-positive DCIS has favourable prognosis with adjuvant systemic therapy. Half of the cases may be occult invasive cancer with true metastasis. In practical settings, clinicians may have to treat these tumours as node-positive small invasive cancers because it is difficult to predict the pathogenesis without exhaustive primary tumour sectioning.
导管原位癌(DCIS)-浸润性乳腺癌-伴淋巴结转移,临床上可视为不同分期:隐匿性浸润癌伴真正转移(T1N1)或纯 DCIS 伴医源性播散(TisN0)。在这项回顾性队列研究中,我们旨在阐明 DCIS 中淋巴结转移的预后影响和可能的发病机制,以改善临床管理。
本研究纳入了 427 例行常规术后 DCIS 诊断并接受前哨淋巴结(SN)活检的患者,采用分子全淋巴结分析。比较 SN 阳性和 SN 阴性患者的临床病理特征和预后。对 SN 阳性患者的原发肿瘤组织进行全面分步切片,以检测隐匿性浸润,并探讨隐匿性浸润的预测因素。中位随访时间为 73.6 个月。
在 427 例患者中,19 例(4.4%)SN 阳性,408 例(95.6%)SN 阴性。与 SN 阴性患者相比,更多的 SN 阳性患者接受了辅助全身治疗(84.2%比 5.4%)。两组 7 年远处无病生存率均良好(SN 阳性组 100%,SN 阴性组 99.7%)。通过检查 1421 张切片,在 19 例 SN 阳性患者中发现了 9 例(47.4%)隐匿性浸润。SN 和非 SN 转移的肿瘤负荷在有和无隐匿性浸润的患者之间相似,并且没有发现隐匿性浸润的预测因素。
伴有辅助全身治疗的 SN 阳性 DCIS 预后良好。其中一半可能是真正转移的隐匿性浸润性癌。在实际情况下,由于缺乏对原发性肿瘤进行全面切片的预测因素,临床医生可能不得不将这些肿瘤视为 SN 阳性的小浸润性癌进行治疗。